Online inquiry

IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ177MR)

This product GTTS-WQ177MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ177MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6811MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ12015MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MM-302
GTTS-WQ6758MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DS-1062
GTTS-WQ14109MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aNGF75
GTTS-WQ11922MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MLN2045
GTTS-WQ3745MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ1485MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ8458MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HspE7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW